India, Feb. 6 -- Zydus Lifesciences on Friday said the US Food and Drug Administration has granted Orphan Drug Designation to Desidustat, its novel oral medication being developed for the treatment of sickle cell disease.
The USFDA grants orphan drug status to support the development of therapies for rare diseases affecting fewer than 200,000 people in the United States, offering incentives to encourage research in areas with significant unmet medical needs.
Commenting on the development, Sharvil Patel, Managing Director of Zydus Lifesciences, said the designation highlights the urgent need for effective therapies for sickle cell disease. He added that the company believes Desidustat has the potential to address this unmet need.
The desi...